tldrdailynews.com logo

Novo Nordisk teams with Langer-founded Vivtex on oral obesity therapies

1 min read
Source: Endpoints News
Novo Nordisk teams with Langer-founded Vivtex on oral obesity therapies
Photo: Endpoints News
TL;DR

Novo Nordisk is partnering with Vivtex, a biotech co-founded by MIT’s Robert Langer, to develop oral obesity therapies, expanding the pharmaceutical giant’s push into obesity drugs.

Topics:businesspharma#novo-nordisk#obesity#oral-drugs#pharma#robert-langer#vivtex
Share this article
  1. Novo Nordisk teams with Langer-founded biotech for oral obesity drugs  Endpoints News
  2. Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess  Fierce Biotech
  3. Novo Nordisk strikes deal with U.S. startup to develop oral obesity, diabetes drugs  statnews.com
  4. Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes  Yahoo Finance
  5. Novo turns to Vivtex for oral obesity biologics in $2.1B deal  FirstWord Pharma

Want the full story? Read the original reporting

Read on Endpoints News